Core Viewpoint - The company, Xinmai Medical (688016.SH), has received a medical device registration certificate from the National Medical Products Administration for its polyethylene glycol embolization microspheres, marking a significant advancement in interventional oncology treatment options [1] Group 1: Product Development - The polyethylene glycol embolization microspheres, named FinderSphere®/Night Pearl™, are the company's first embolization product developed for interventional oncology [1] - This product aims to provide more precise and efficient treatment options for Transarterial Chemoembolization (TACE) procedures, benefiting a larger number of cancer patients in China [1] Group 2: Existing and Pipeline Products - In addition to the new product, the company has already launched the Tipspear®/Piercing Arrow™ transjugular intrahepatic portosystemic shunt (TIPS) kit in China [1] - The company is also developing several other products in the interventional oncology field, including the innovative medical device HepaFlow®/Bridge to the Sky™ TIPS covered stent system, as well as hemostatic occlusion systems and microcatheters [1] Group 3: Future Commitment - The company is committed to the innovative research and application promotion of high-end medical devices in aortic, peripheral vascular, and interventional oncology fields, aiming to benefit more patients both domestically and internationally [1]

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Tuomai Medical, has received a medical device registration certificate from the National Medical Products Administration for a polyethylene glycol embolization microsphere, marking a significant advancement in the company's interventional oncology product line [1] Group 1 - The registration certificate number is Guo Xie Zhu Ren 20263130187, valid from January 28, 2026, to January 27, 2031 [1] - The product is classified as a Class III medical device, intended for embolization treatment of hypervascular malignant tumors in solid organs [1] - This product represents the company's first embolization product in the field of tumor interventional therapy, potentially offering improved treatment options [1] Group 2 - The product must obtain a production license before it can be sold, and the sales situation remains uncertain, making it difficult to predict its impact on revenue [1]

Core Viewpoint - The company Xinmai Medical (688016.SH) announced that its wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The product is specifically designed for the treatment of hypervascular malignant tumors [1] - The registration certificate was issued by the National Medical Products Administration [1] - The subsidiary involved in this development is Shanghai Tuomai Medical Technology Co., Ltd. [1]

Market Overview - The medical device sector increased by 0.9% on February 4, with SAIKOSHI leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Performers - SAIKOSHI (688338) closed at 32.11, up 10.15% with a trading volume of 63,600 shares and a transaction value of 197 million [1] - SHUOSHI BIO (6638889) closed at 71.46, up 5.69% with a trading volume of 15,900 shares and a transaction value of 113 million [1] - BAOLAIT (300246) closed at 13.51, up 2.74% with a trading volume of 166,100 shares and a transaction value of 224 million [1] Underperformers - KANGZHONG MEDICAL (688607) closed at 57.80, down 4.26% with a trading volume of 46,300 shares [2] - SINO MEDICAL (688108) closed at 22.70, down 3.77% with a trading volume of 170,600 shares and a transaction value of 387 million [2] - SANYOU MEDICAL (688085) closed at 21.05, down 3.08% with a trading volume of 39,800 shares and a transaction value of 84 million [2] Capital Flow - The medical device sector experienced a net outflow of 132 million from institutional investors, while retail investors saw a net outflow of 191 million [2] - Speculative funds had a net inflow of 323 million into the sector [2] Individual Stock Capital Flow - MAIRUI MEDICAL (300760) had a net inflow of 86.91 million from institutional investors, while retail investors had a net outflow of 169 million [3] - LIANSHENG MEDICAL (688271) saw a net inflow of 44.32 million from institutional investors, with a net outflow of 76.86 million from retail investors [3] - HUAKANG CLEAN (301235) had a net inflow of 31.25 million from institutional investors, while retail investors experienced a net outflow of 52.92 million [3]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The medical device bidding market is expected to maintain high prosperity in 2025, driven by policy and demand resonance, with a projected market size of CNY 193.76 billion, representing a year-on-year growth of 24% [3][11] - The upward trend for medical device companies is clear for 2026, with multiple policies expected to support the continuous development of medical innovation [4][29] - The report emphasizes the importance of high-end product localization and innovation in driving growth for leading domestic companies [33][41] Summary by Sections Bidding Review - The medical device bidding market in 2025 is projected to reach CNY 193.76 billion, with a year-on-year increase of 24%, second only to the peak in 2022 [3][11] - Monthly bidding trends show sustained high levels, with procurement amounts from July to December ranging from CNY 134 billion to CNY 285 billion [3][11] - Key segments such as medical imaging equipment and radiation therapy devices are expected to see significant growth, with year-on-year increases of 35.37% and 36.34% respectively [3][16] 2026 Outlook - The report anticipates a clear upward turning point for medical device companies in 2026, supported by policies aimed at promoting medical innovation and equipment updates [4][29] - The implementation of large-scale equipment updates and consumer replacement policies is expected to further stimulate market demand [4][29] - The report highlights the potential for domestic companies to benefit from high-end product upgrades and the commercialization of brain-computer interface technologies [4][50] Investment Recommendations - The report suggests focusing on leading domestic companies that are enhancing their high-end and intelligent medical device offerings, such as Mindray, United Imaging, and KaiLi Medical [4][33] - It also recommends monitoring companies involved in brain-computer interfaces and domestic robotics, which are expected to see significant growth in the coming years [4][50]

Group 1 - The core point of the article is that Opcon Vision (300595) reported a total of 62,579 shareholders as of January 30, 2026 [1]

Group 1 - The core point of the article is that Yuyue Medical (002223) has over 50,000 shareholders as of January 30, 2026 [1]

Core Viewpoint - The company, Weili Medical, has received notification from the EU regulatory authority regarding the addition of multiple products to its EU Medical Device Regulation (MDR) certification [1] Group 1 - The company has recently been granted new EU MDR certifications for several products [1]

Core Viewpoint - The company, Weili Medical (603309.SH), has received notification from the EU announcement agency regarding the addition of multiple products to its EU Medical Device Regulation (MDR) certification [1] Group 1 - The newly certified products comply with the latest EU medical device regulations, indicating they meet the current market access requirements in the EU [1] - The EU MDR certification allows the company to legally sell its products in relevant overseas markets, enhancing the promotion and sales of its products in those markets [1]

Core Viewpoint - The company, Weili Medical (603309.SH), has received notification from the EU announcement agency regarding the addition of multiple products to its EU Medical Device Regulation (MDR) certification, indicating compliance with the latest EU medical device regulations and enabling legal sales in relevant overseas markets [1] Group 1 - The company has obtained EU MDR certification for several products, which signifies adherence to the latest EU medical device regulatory requirements [1] - The new certification allows the company to meet the latest market access conditions in the EU, facilitating the promotion and sales of its products in corresponding markets [1]